"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Primary Polycythemia
- Polycythemia, Primary
- Polycythemias, Primary
- Primary Polycythemias
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Polycythemia Ruba Vera
- Polycythemia Ruba Veras
- Ruba Vera, Polycythemia
- Ruba Veras, Polycythemia
- Vera, Polycythemia Ruba
- Veras, Polycythemia Ruba
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 05; 39(5):1135-1145.
-
Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach. Adv Clin Exp Med. 2025 Jan; 34(1):25-32.
-
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
-
Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 03 14; 7(5):712-717.
-
Ischemic Jejunal Stricture Secondary to Polycythemia Vera. Dig Dis Sci. 2023 04; 68(4):1077-1079.
-
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
-
Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020 03 24; 4(6):1115-1130.
-
Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-characteristics along with a validation of 2016 WHO criteria. Eur J Haematol. 2019 Dec; 103(6):558-563.
-
[Myeloproliferative neoplasms - Update on diagnosis and treatment]. Ther Umsch. 2019; 76(9):487-495.